Abstract 1444P
Background
In the United States, uniquely American risk factors have led to a rise in the incidence of esophageal adenocarcinoma. In contrast, Asians have generally shown a predominance of esophageal squamous cell carcinoma (SCC), and this has held among Asian-Americans. However, limited investigation of esophageal cancer within Asian-Americans has been conducted in recent years.
Methods
The Surveillance, Epidemiology, and End Results (SEER) Incidence Database was queried for patients from 2004-2020 classified as Asian/Pacific Islander and diagnosed with esophageal adenocarcinoma or squamous cell carcinoma. Descriptive statistics and multivariate models were utilized to compare incidence, cancer characteristics, treatment details, and survival in patients with esophageal adenocarcinoma and SCC.
Results
During this time, 2103 (73.71%) Asian-Americans presented with esophageal SCC compared to 750 (26.29%) with adenocarcinoma. Patients with SCC were diagnosed at a significantly older age (68.09 vs 66.10, p=<0.0001) and had a larger distribution of females (28.72% vs 15.20%, p<0.0001) than those with adenocarcinoma. The distribution of tumor stage was significantly different across these two groups (p<0.0001), with 292 (38.93%) adenocarcinoma patients diagnosed at stage IV compared to 546 (25.96%) patients with SCC. Cox regression analysis revealed that SCC was independently associated with worse survival (Hazard Ratio 1.115 (1.08-1.233)) compared to esophageal adenocarcinoma. Table: 1444P
Histological subtype | p-value | ||
Squamous cell carcinoma (N = 2103), N (%) | Adenocarcinoma (N = 750), N (%) | ||
Age, mean (years) | 68.09 | 66.10 | <0.0001 |
Sex | <0.0001 | ||
Female | 604 (28.72) | 114 (15.20) | |
Male | 1499 (71.28) | 636 (84.80) | |
Derived stage | <0.0001 | ||
I | 196 (9.32) | 72 (9.60) | |
II | 379 (18.02) | 97 (12.93) | |
III | 547 (26.01) | 166 (22.13) | |
IV | 546 (25.96) | 292 (38.93) | |
Unknown | 435 (20.68) | 123 (16.40) | |
Location of tumor | <0.0001 | ||
Upper third | 276 (13.12) | 11 (1.47) | |
Middle third | 692 (32.91) | 43 (5.73) | |
Lower third | 547 (26.01) | 566 (75.47) | |
Unclear/NOS | 588 (27.96) | 130 (17.33) | |
Cause of death | <0.0001 | ||
Alive | 452 (21.49) | 177 (23.6) | |
Esophageal cancer | 1300 (61.82) | 411 (54.8) | |
Other cause of death | 351 (16.69) | 162 (21.6) |
Conclusions
SCC remains the predominant histological subtype of esophageal cancer within Asian-Americans. Several factors may contribute to this, including BMI, immigration history, and retained cultural practices. However, adenocarcinoma should not be missed in this cohort. The later stage diagnosis of adenocarcinoma suggests that methods to improve early detection are necessary, and poorer survival of the SCC cohort indicates an opportunity to improve treatment paradigms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1435P - Immunomodulatory effects and improved survival of PG2 plus preoperative chemoradiotherapy in patients with locally advanced esophageal cancer
Presenter: Lai-Man Mok
Session: Poster session 18
Resources:
Abstract
1436P - Better overall survival of male versus female patients with advanced gastric adenocarcinoma
Presenter: Minggui Pan
Session: Poster session 18
Resources:
Abstract
1437P - Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up
Presenter: Marcia Cruz-Correa
Session: Poster session 18
Resources:
Abstract
1438P - First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW
Presenter: Yoon-Koo Kang
Session: Poster session 18
Resources:
Abstract
1439P - ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study
Presenter: John Strickler
Session: Poster session 18
Resources:
Abstract
1440P - Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): A single-arm, open-label, phase II trial.
Presenter: Chao Cheng
Session: Poster session 18
Resources:
Abstract
1441P - Clinical application of a machine learning-based pathomics signature for predicting lymph node metastasis in early gastric cancer
Presenter: Weiyao Li
Session: Poster session 18
Resources:
Abstract
1442P - Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy
Presenter: Hiroki Osumi
Session: Poster session 18
Resources:
Abstract
1443P - Association between fruquintinib-induced hypertension and clinical outcomes from FRUTIGA, a phase III study of fruquintinib plus paclitaxel in previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
Presenter: Shukui Qin
Session: Poster session 18
Resources:
Abstract
1445P - Novel DNA methylation markers for early detection of cardia gastric adenocarcinoma and esophageal squamous cell carcinoma
Presenter: Zhiyuan Fan
Session: Poster session 18
Resources:
Abstract